Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://link.springer.com/journal/41824/collections
Articles
Page 5 of 6
-
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:8
-
Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:7 -
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers
Brain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the...
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:6 -
Automated synthesis of [11C]L-glutamine on Synthra HCN plus synthesis module
L-Glutamine (L-Gln) is the most abundant amino acid present in the human body and is involved in numerous metabolic pathways. Glutaminolysis is the metabolic process deployed by many aggressive cancers such as...
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:5 -
Radiosynthesis and in vivo evaluation of 11C-labeled BMS-193885 and its desmethyl analog as PET tracers for neuropeptide Y1 receptors
Neuropeptide Y (NPY) has been implicated in a wide variety of physiological processes, including feeding, learning, memory, emotion, cardiovascular homeostasis, hormone secretion, and circadian rhythms. NPY Yl...
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:4 -
Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals
Clinically applied radiopharmaceuticals have to meet quality release criteria like a high radiochemical yield and radiochemical purity. Many radiopharmaceuticals do not have marketing authorization and have no...
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:3 -
The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:2 -
Synthesis of a benzoxazinthione derivative of tanaproget and pharmacological evaluation for PET imaging of PR expression
The histological evaluation of estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer lesions from biopsy tissue can stratify patients to receive endocrine therapy. Furthermore, PR e...
Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:1 -
An alternative methodology for the determination of the radiochemical purity of 11C-methionine
[11C]Methionine ([11C]MET) acts as an oncological radiopharmaceutical for measuring increased protein synthesis in brain tumours while having low uptake in normal brain an. In several Latin American countries, th...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:15 -
A high molar activity 18F-labeled TAK-875 derivative for PET imaging of pancreatic β-cells
The free-fatty acid receptor-1 (FFA-1) is expressed by β-cells and is a promising target for molecular imaging of functional β-cell mass. Recently, the ((3-[18F]fluoropropyl)sulfonyl)propoxy-derivative of the hig...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:14 -
Publisher Correction to EJNMMI Radiopharmacy and Chemistry Volume 1 (2016)
The metadata in the HTML format of these original articles (Eppard et al., 2017; Decristoforo & Patt, 2017; Domnanich et al., 2017; Chan et al., 2017; Jovalekic et al., 2017; Zhang & Villalobos, 2017; Meckel e...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:13 -
Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center
We recently upgraded our [18F]fludeoxyglucose (FDG) production capabilities with the goal of futureproofing our FDG clinical supply, expanding the number of batches of FDG we can manufacture each day, and improvi...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:12 -
Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([18F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression
Several P-glycoprotein (P-gp) substrate tracers are available to assess P-gp function in vivo, but attempts to develop a tracer for measuring expression levels of P-gp have not been successful. Recently, (Z)-2...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:11 -
Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid
To study MMP activity in vivo in disease, several radiolabeled MMP inhibitors functioning as radiotracers have been evaluated by means of SPECT and PET. Unfortunately, most of them suffer from metabolic instab...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:10 -
A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy
Targeted radionuclide therapy is a highly efficient but still underused treatment modality for various types of cancers that uses so far mainly readily available β-emitting radionuclides. By using α-particle e...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:9 -
Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4
[11C]erlotinib has been proposed as a PET tracer to visualize the mutational status of the epidermal growth factor receptor (EGFR) in cancer patients. For clinical use, a stable, reproducible and high-yielding ra...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:8 -
19th European Symposium on Radiopharmacy and Radiopharmaceuticals (ESRR’18)
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3(Suppl 1):7 -
Preparation and preclinical evaluation of a 68Ga-labelled c(RGDfK) conjugate comprising the bifunctional chelator NODIA-Me
We recently developed a chelating platform based on the macrocycle 1,4,7-triazacyclononane with up to three, five-membered azaheterocyclic arms for the development of 68Ga- and 64Cu-based radiopharmaceuticals. He...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:6 -
A new two-strip TLC method for the quality control of technetium-99m mercaptoacetyl-triglycine (99mTc-MAG3)
99mTc-mercaptoacetyl-triglycine (99mTc-MAG3) has been used for dynamic renal imaging since about 30 years. Free pertechnetate (99mTcO4), colloidal 99mTc ((99mTcO2)n), 99mTc-tartrate (precursor), precomplexes (99m
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:5 -
Synthesis of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
Overexpression of prostatic membrane antigen (PSMA) is associated with the progression and prognosis of prostate cancer. There are numerous studies using this peptide with the 68Ga radionuclide. Previous methods ...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:4 -
Production of novel diagnostic radionuclides in small medical cyclotrons
The global network of cyclotrons has expanded rapidly over the last decade. The bulk of its industrial potential is composed of small medical cyclotrons with a proton energy below 20 MeV for radionuclides prod...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:3 -
Metabolite profiling with HPLC-ICP-MS as a tool for in vivo characterization of imaging probes
Current analytical methods for characterizing pharmacokinetic and metabolic properties of positron emission tomography (PET) and single photon emission computed tomography (SPECT) probes are limited. Alternati...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:2 -
Radiosynthesis and evaluation of an 18F–labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma
Analogues of exendin-4 have been radiolabeled for imaging the glucagon-like peptide type 1 receptors (GLP-1R) which are overexpressed in insulinoma. The aim of this research was to synthesize an 18F–labeled silic...
Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:1 -
Convergent synthesis of 13N-labelled Peptidic structures using aqueous [13N]NH3
Nitrogen-13 has a 10-min half-life which places time constraints on the complexity of viable synthetic methods for its incorporation into PET imaging agents. In exploring ways to overcome this limitation, we h...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:16 -
Generation of fluorescently labeled tracers – which features influence the translational potential?
Given the increasing exploration of fluorescent tracers in the field of nuclear medicine, a need has risen for practical development guidelines that can help improve the translation aspects of fluorescent trac...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:15 -
Production and separation of 43Sc for radiopharmaceutical purposes
The favorable decay properties of 43Sc and 44Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage 43Sc (T1/2 = 3.89 h, Eβ+ av = 476 keV [8...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:14 -
Improving the stability of 11C–labeled L-methionine with ascorbate
Carbon-11 labeled L-methionine (11C–MET) is a popular tracer used in the clinic for imaging brain tumors with positron emission tomography. However, the stability of 11C–MET in its final formulation is not well d...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:13 -
Position statement on radiopharmaceutical production for clinical trials
The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:12 -
Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:11 -
An efficient preparation of labelling precursor of [11C]L-deprenyl-D2 and automated radiosynthesis
The synthesis of [11C]L-deprenyl-D2 for imaging of astrocytosis with positron emission tomography (PET) in neurodegenerative diseases has been previously reported. [11C]L-deprenyl-D2 radiosynthesis requires a pre...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:10 -
Sulfur - fluorine bond in PET radiochemistry
The importance of the sulfur-fluorine bond is starting to increase in modern medicinal chemistry literature. This is due to a better understanding of the stability and reactivity of this moiety depending on th...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:9 -
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as an Appendix of Part B of the EANM “Guidelines on Good Radiopha...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:8 -
An updated radiosynthesis of [18F]AV1451 for tau PET imaging
[18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide dose...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:7 -
Pretargeting for imaging and therapy in oncological nuclear medicine
Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achi...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:6 -
47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes
Radiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionucli...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:5 -
Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography
The somatostatin receptor subtype 2 (sstr2) is expressed on a majority of luminal breast cancers, however SPECT and scintigraphy imaging with agonistic sstr2 probes has been sub-optimal. High affinity antagoni...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:4 -
Synthesis, gallium labelling and characterization of P04087, a functionalized phosphatidylserine-binding peptide
Radiolabeled phosphatidylserine (PS)-binding peptides represent an innovative strategy for molecular imaging of apoptosis and thrombus. The hexapeptide PGDLSR was described as a selective and high affinity lig...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:3 -
[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-t...
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:2 -
Nomenclature for radiopharmaceuticals, consultation of your opinion!
Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:1 -
Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis
αVβ3, αVβ5 and α5β1 integrins are known to be involved in carcinogenesis and are overexpressed in many types of tumours compared to healthy tissues; thereby they have been selected as promising therapeutic target...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:16 -
Automation of the Radiosynthesis of Six Different 18F-labeled radiotracers on the AllinOne
Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible man...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:15 -
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in ...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:14 -
Strategies to facilitate the discovery of novel CNS PET ligands
Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclini...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:13 -
Are we “preparing” radiopharmaceuticals?
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:12 -
18th European Symposium on Radiopharmacy and Radiopharmaceuticals
OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1(Suppl 1):10 -
New protein deposition tracers in the pipeline
Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed t...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:11 -
Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therap...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:9 -
44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:8 -
Improved GMP-compliant multi-dose production and quality control of 6-[18F]fluoro-L-DOPA
6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) is a frequently used radiopharmaceutical for detecting neuroendocrine and brain tumors and for the differential diagnosis of Parkinson’s disease. To meet the dem...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:7 -
Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol
Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields are defined by temperature, period of labeling, amount of precursor, pH etc. As ...
Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:6
EJNMMI Reports - Kindly explore our collections here
EANM'24 - Future Congress!
Future Congress
37th Annual Congress of the European Association of Nuclear Medicine
October 19 – 23, 2024
Hamburg, Germany
CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/
EJNMMI Journal Family and EANM Springer Award
EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.
Do you want to publish your paper open access?
Details of the OpenChoice option in EJNMMI are available in the submission guidelines.
If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.
Please check the agreement details by participating country here.
Follow
- ISSN: 2365-421X (electronic)